Alectinib and lorlatinib function by modulating EMT-related proteins and MMPs in NSCLC metastasis

Area of Science:

• Oncology
• Molecular Biology
• Cancer Metastasis Research

Background:

• Advanced non-small cell lung cancer (NSCLC) frequently involves brain metastasis, a primary driver of mortality.
• Anaplastic lymphoma kinase (ALK) gene rearrangements are common in lung cancer brain metastases.
• The precise mechanisms of action for ALK inhibitors like alectinib and lorlatinib against brain metastasis remain incompletely understood.

Purpose of the Study:

• To investigate the molecular mechanisms by which alectinib and lorlatinib affect non-small cell lung cancer (NSCLC) brain metastasis.
• To explore the impact of these ALK inhibitors on epithelial-mesenchymal transition (EMT) markers and matrix metalloproteinases (MMPs).

Main Methods:

• Utilized H3122 cells, known for ALK rearrangements.
• Assessed mRNA and protein levels of EMT markers (VIM, FN1) and MMPs (MMP-9, MMP-7).
• Evaluated the effects of alectinib and lorlatinib, both individually and in combination, in a dose- and time-dependent manner, alongside cell viability and migration assays.

Main Results:

• Elevated levels of VIM, FN1, MMP-9, and MMP-7 were observed in H3122 cells.
• Alectinib and lorlatinib treatment significantly reduced these elevated levels.
• Both drugs inhibited cell viability and migration, with combination therapy demonstrating superior effectiveness.

Conclusions:

• Alectinib and lorlatinib may exert their anti-metastatic effects in ALK-positive NSCLC by downregulating MMPs and EMT pathways.
• The combination of alectinib and lorlatinib offers a potentially more potent therapeutic strategy for managing NSCLC brain metastasis.